Alexandra MacLean
Vorstandsvorsitzender bei AVENUE THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Alexandra MacLean is currently the Chief Executive Officer & Director at Avenue Therapeutics, Inc. She is also a Director at Access Vascular, Inc. Previously, she worked as an Entrepreneur in Residence at Fortress Biotech, Inc. and as the Head-Licensing & Business Development at Imbrium Therapeutics LP.
Dr. MacLean holds a graduate degree from the University of Cambridge, an undergraduate degree from McGill University, an MBA from the University of Colorado Boulder, and a doctorate from Vagelos College of Physicians & Surgeons.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
06.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Alexandra MacLean
Unternehmen | Position | Beginn |
---|---|---|
AVENUE THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.08.2022 |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Alexandra MacLean
Unternehmen | Position | Ende |
---|---|---|
FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 01.07.2022 |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Corporate Officer/Principal | - |
Ausbildung von Alexandra MacLean
Vagelos College of Physicians & Surgeons | Doctorate Degree |
University of Colorado Boulder | Masters Business Admin |
University of Cambridge | Graduate Degree |
McGill University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AVENUE THERAPEUTICS, INC. | Health Technology |
FORTRESS BIOTECH, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |